AMLX Q1 2024 Earnings — Amylyx Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMLXAmylyx Pharmaceuticals, Inc.

$1B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$89M+24.1% YoY

Gross Profit

-$28M-31.3% margin

Operating Income

-$122M-137.8% margin

Net Income

-$119M-134.0% margin

EPS (Diluted)

$-1.75

QoQ Revenue Growth

-18.3%

Cash Flow

Operating Cash Flow

-$489,000

Free Cash Flow

-$556,000

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$417M

Total Liabilities

$93M

Stockholders' Equity

$324M

Cash & Equivalents

$171M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$89M	$71M	+24.1%
Gross Profit	-$28M	$66M	-142.0%
Operating Income	-$122M	-$2M	-5848.9%
Net Income	-$119M	$2M	-7652.0%